MedTrace Logo

Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma

NCT05228808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-02-08

No results posted yet for this study

Summary

Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an unusually high rate of young-onset pancreatic carcinoma. Pancreatic ductal adenocarcinoma is by far the most common histologic subtype of pancreatic malignancy. Programmed death ligand-1 (PD-L1) is a type I trans-membrane glycoprotein. It has an important prognostic and predictive value in various neoplasms. To date, few studies have addressed the potential prognostic role of PD-L1 in pancreatic carcinoma, so knowledge about its prognostic value needs further elucidation.

Conditions

  • Pancreatic Adenocarcinoma

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Nagwa Ahmed, Lecturer · Sohag University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-06-01
Completion
2022-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05228808 on ClinicalTrials.gov